STICs and STONes: A Randomised, Phase II, Double-Blind, Placebo-Controlled Trial of Aspirin in Chemoprevention of Ovarian Cancer in Women with BRCA1 and BRCA2 Mutations [ 2017 - 2021 ]

Research Grant

Researchers: Prof Kelly-Anne Phillips (Principal investigator) ,  A/Pr Alison Brand ,  A/Pr Clare Scott ,  Dr Colin Stewart ,  Prof Amit Oza
View all 6 related researchers

Brief description Women with a BRCA1 or BRCA2 gene abnormality are at increased risk of ovary and fallopian tube (O&FT) cancers and often have their O&FTs removed to prevent cancer. Microscopic cancers are often seen at the time of surgery. Some studies suggest that aspirin might reduce O&FT cancer risk. This study will assign women to daily aspirin or placebo for 6-24 months before their preventive O&FT surgery. It will provide a better understanding of how O&FT cancers start and the influence aspirin may have.

Funding Amount $AUD 669,715.34

Funding Scheme Project Grants

Notes Standard Project Grant